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Oxidative stress attenuates the NO-cGMP pathway, e.g. in
the vascular system, through scavenging of free NO radi-
cals by superoxide O2•-, by inactivation of soluble guany-
lyl cyclase (sGC) via oxidation of its central Fe2+ ion, and
by down-regulation of sGC protein levels. While the
former pathways are well established, the molecular
mechanisms underlying the latter are still obscure. Using
oxidative sGC inhibitor ODQ we demonstrate rapid
down-regulation of sGC protein in mammalian cells. Co-
incubation with proteasomal inhibitor MG132 results in
accumulation of ubiquitinated sGC whereas sGC activator
BAY 58–2667 prevents ubiquitination. ODQ-induced
down-regulation of sGC is mediated through selective
ubiquitination of its b subunit, and BAY 58–2667 abro-
gates this effect. Ubiquitination of sGC-b is dramatically
enhanced by E3 ligase CHIP. Our data indicate that oxida-
tive stress promotes ubiquitination of sGC b subunit
through E3 ligase CHIP, and that sGC activator 58–2667
reverts this effect, most likely through stabilization of the
heme-free b subunit. Thus the deleterious effects of oxida-
tive stress can be counter-balanced by an activator of a key
enzyme of vascular homeostasis.
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